10.86
Tyra Biosciences Inc stock is traded at $10.86, with a volume of 224.32K.
It is down -0.55% in the last 24 hours and up +13.24% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$10.92
Open:
$10.96
24h Volume:
224.32K
Relative Volume:
0.68
Market Cap:
$576.56M
Revenue:
-
Net Income/Loss:
$-83.74M
P/E Ratio:
-6.7453
EPS:
-1.61
Net Cash Flow:
$-64.98M
1W Performance:
+6.05%
1M Performance:
+13.24%
6M Performance:
-32.92%
1Y Performance:
-45.97%
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TYRA
Tyra Biosciences Inc
|
10.86 | 544.54M | 0 | -83.74M | -64.98M | -1.61 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-21-25 | Resumed | Piper Sandler | Overweight |
Jan-07-25 | Initiated | UBS | Buy |
Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
Aug-15-24 | Initiated | Piper Sandler | Overweight |
Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
Jun-30-23 | Initiated | Wedbush | Outperform |
Feb-03-23 | Initiated | Oppenheimer | Outperform |
Jun-23-22 | Initiated | H.C. Wainwright | Buy |
Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
Oct-11-21 | Initiated | BofA Securities | Buy |
Oct-11-21 | Initiated | Cowen | Outperform |
Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Tyra Biosciences Rises On Precision Medicine Hopes And Analyst Support - Finimize
What makes Tyra Biosciences Inc. stock price move sharplyRisk Adjusted Stock Signals - Newser
Why Tyra Biosciences Inc. stock attracts strong analyst attentionFree Access to Community with 300% Return - Newser
How Tyra Biosciences Inc. stock performs during market volatilityFree Capital Growth Strategies - Newser
Tyra Biosciences Insider Lowered Holding By 58% During Last Year - simplywall.st
Advanced Urothelial Carcinoma Clinical Trials 2025: EMA, PDMA, - openPR.com
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Eastern Progress
Tyra Biosciences' TYRA-300 Emerges as Dual-Threat Therapy, Poised to Drive Clinical and Market Momentum - AInvest
New TYRA-300 Preclinical Data Reveals Promising Results for Rare Bone Growth Disorder Treatment - Stock Titan
Where are the Opportunities in (TYRA) - news.stocktradersdaily.com
Tyra Biosciences’ (TYRA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC - Targeted Oncology
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - Longview News-Journal
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Value Index - MarketScreener
Revolutionary Oral Treatment for Bladder Cancer Begins Phase 2 Trial: First Patient Receives TYRA-300 - Stock Titan
When the Price of (TYRA) Talks, People Listen - news.stocktradersdaily.com
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
California State Teachers Retirement System Sells 2,366 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 10,426 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
RA Capital Boosts Stake in Tyra Biosciences (TYRA) to 22.4% | TYRA Stock News - GuruFocus
Kantar appoints Jeff Greenspoon as CEO, Americas - The Globe and Mail
June Brings on Some Huge Insider Buying - 24/7 Wall St.
Kernaghan buying at Western Forest Products (WEF) - The Globe and Mail
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Two Sigma Investments LP Has $643,000 Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Tyra Biosciences Soars 10.71% on Insider Buying - AInvest
Two Sigma Investments LP Grows Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World
Jane Street Group LLC Acquires Shares of 26,297 Skillz Inc. (NYSE:SKLZ) - Defense World
Schwab International Equity ETF (NYSEARCA:SCHF) Shares Sold by Squarepoint Ops LLC - Defense World
Zumiez Inc. (NASDAQ:ZUMZ) Shares Sold by Two Sigma Investments LP - Defense World
Squarepoint Ops LLC Invests $253,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Two Sigma Advisers LP Purchases 92,800 Shares of ThredUp Inc. (NASDAQ:TDUP) - Defense World
Two Sigma Advisers LP Takes $162,000 Position in Innovex International, Inc. (NYSE:INVX) - Defense World
Two Sigma Advisers LP Makes New $171,000 Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Bank of America Corp DE Purchases 11,804 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Klondike Silver (CVE:KS) Trading Up 50% – What’s Next? - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of “Buy” from Analysts - Defense World
Wishbone Gold (LON:WSBN) Trading 21.6% Higher – Should You Buy? - Defense World
AGM Group (NASDAQ:AGMH) Rating Increased to Hold at Wall Street Zen - Defense World
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of “Buy” from Analysts - Defense World
BlackRock MuniYield Michigan Quality Fund, Inc. (NYSE:MIY) Short Interest Up 21.4% in May - Defense World
Motorcar Parts of America, Inc. (NASDAQ:MPAA) Shares Sold by Two Sigma Advisers LP - Defense World
Trend Tracker for (TYRA) - news.stocktradersdaily.com
PortfolioPlus S&P 500 ETF (NYSEARCA:PPLC) Shares Up 2.2% – What’s Next? - Defense World
BNP Paribas Financial Markets Purchases New Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Deutsche Bank AG Acquires 6,466 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Millennium Management LLC Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Tyra Bioscience Holds 2025 Annual Stockholders Meeting - TipRanks
TYRA Stock: Upcoming Oppenheimer Meeting Announcement | TYRA Sto - GuruFocus
Bank of America Corp DE Sells 1,164,431 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):